BRIEF-Senti Biosciences Completes Enrollment In Phase 1 Clinical Trial Of Senti-202

Senti Biosciences, Inc. +0.73% Post

Senti Biosciences, Inc.

SNTI

0.94

0.94

+0.73%

0.00% Post

- Senti Biosciences Inc SNTI.O:

  • SENTI BIOSCIENCES COMPLETES ENROLLMENT IN PHASE 1 CLINICAL TRIAL OF SENTI-202 FOR THE TREATMENT OF RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA (R/R AML)

Source text: ID:nGNX9mWWcd

Further company coverage: SNTI.O